Abstract
BackgroundThe functions of the HOXA 5, HOXA 9, and PRDM16 are concerned with embryonic growth and the regulation of adult hematopoietic cells differentiation. The HOXA5, HOXA9, and PRDM16 are expressed in the majority of solid cancers and several hematological malignancies, including myeloproliferative disease and acute leukemia. The function and prognostic values of HOXA5, HOXA9, and PRDM16 quantitative PCR expression in novel patients with acute myeloblastic leukemia (AML) were to be studied. MethodsThis prospective case-control study was performed on 60 newly diagnosed AML patients and 40 healthy subjects acting as a control group. The patients underwent CBC, BM analysis, HOXA5, HOXA9, and PRDM16 expression by qRT-PCR testing. ResultsHigh expressions of HOXA5, HOXA9, and PRDM16 were significantly prevalent in patients compared with the control. The highest incidence of expression was found in AML patients with minimal maturation and acute megakaryoblastic leukemia (M1/M7). Interestingly, high levels of HOXA5, HOXA9, and PRDM16 expressions were correlated with older age and hepatosplenomegaly associated with poor clinical outcome, shorter overall and disease-free survival than low levels of HOXA5, HOXA9, and PRDM16 expressions. ConclusionHigh HOXA and PRDM16 expressions predict bad outcomes and are associated with weak prognostic factors which can promote new therapeutic trends for AML.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
